Company intelligence / Profile preview

ILEX Oncology, Inc.

San Antonio, Texas, United States

Ownership: Private
Employees: ~300
Development stage: Commercial

Overview

ILEX successfully brought Campath to market with regulatory approvals in the US/EU for chronic lymphocytic leukemia. It had several additional oncology compounds at various clinical stages—including clofarabine and ILX‑651—plus preclinical programs focused on angiogenesis inhibition and novel chemotypes. The company was recognized as one of the few biotechs to achieve product commercialization prior to its $1B acquisition by Genzyme Corporation in mid‑2004.[1][2]

Therapeutic areas: HematologyEndocrinologyOncology
Modalities: Small molecules (e.g., clofarabine, NM3)Monoclonal antibodies (e.g., Campath/alemtuzumab)Synthetic peptides (e.g., ILX‑651/dolastatin analogs)[6]Angiogenesis inhibitors[5][6]
Industry: Biotech

Drug pipeline

3 assets

tasidotin hydrochloride

Preclinical

Indications: Solid tumors, Prostate cancer

2 more assets in the full pipeline.

Request access →

Partnerships

British Biotech plc—contracted development services for marimastatAbgenix—collaboration on fully human anti-MUC1 antibody therapyMillennium Pharmaceuticals—joint venture partnership before full buyout by ILEX.[5]

Beyond the preview

Go deeper on ILEX Oncology, Inc..

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on ILEX Oncology, Inc..

Explore the full profile